« XTL and DOV Pharmaceuticals, Agreed on Worldwide Rights to Bicifadine | Main | Green Tea is Source Of Potential Potent and Safe Antibacterial »

Jan17
Denderon Corp.’s BLA for PROVENGE® under USFDA Priority Review Status for the Treatment of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer

Dendreon Corporation (Nasdaq: DNDN)’s Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) has been accepted and assigned priority review status by the USFDA.

PROVENGE® (sipuleucel-T) is Dendreon Corp.’s investigational active cellular immunotherapy for the treatment of asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer.

Dendreon_Corporation.gifA product under USFDA priority review status will be granted decision six months from filing and is assigned to products that if approved would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious or life-threatening disease.

According to Mitchell H. Gold, president and chief executive officer of Dendreon:

"Clinical trials have shown that PROVENGE increases survival and is generally well tolerated in men with late-stage prostate cancer, a highly prevalent disease for which there are currently few available treatment options.

We are extremely pleased the FDA has granted priority review to PROVENGE, which may represent an important new treatment option for men suffering from prostate cancer."

Under late stage clinical development for the treatment of advanced prostate cancer, PROVENGE® (sipuleucel-T) is an investigational product that may represent the first in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system.

Source: Dendreon Corp.


0 Comments/Trackbacks




submit a trackback

TrackBack URL for this entry:

post a comment

Name, Email Address, and URL are not required fields.





Comment Preview

« XTL and DOV Pharmaceuticals, Agreed on Worldwide Rights to Bicifadine | Main | Green Tea is Source Of Potential Potent and Safe Antibacterial »

Advertise

Watch the Digital Health Revolution


sponsored ads



subscribe


Prefer Email?
Subscribe below-

Enter your Email:


Powered by FeedBlitz What's this?

Current News

Support This Blog

top blogs

business social media

Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

BIZZlogos - Add your logo - free link to your site
BIZZphotos - Add photos of your products and people
BIZZprofiles - Submit your profile and build your online visibility
BIZZspotlight - Spotlight your business with free links
BIZZvideos - Videos about businesses, products and business people.
BIZZbites - "Digg" for Business - Submit your articles and posts

Know More Media - Health Care / Pharmaceutical / Fitness

know more media network

View Network Map

Network Feed List (OPML)

Know More Media Network
Feed


we support unitus

PRWeb

Influencer



PharmaGazette is a member of the Know More Media network of business related blogs.

Here are some current headlines from some of our business publications:

ProductivityGoal

CallCenterScript

AdHurl

TheBizofKnowledge

LandingTheDeal

CustomersAreAlways

HealthCareVox

BrainBasedBusiness

TheInsurancePolicy

MarketingBlurb